Allogene Therapeutics Inc (ALLO) — Financial Flexibility Index

Latest as of September 2025: -0.24x

Allogene Therapeutics Inc (ALLO) has a Financial Flexibility Index of -0.24x as of September 2025. Free cash flow of $-29.45 Million (operating CF $-29.69 Million minus capex $243.00K) represents 0% of total liabilities ($124.44 Million). Also explore Allogene Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.24x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-29.45 Million
Operating CF − Capex

Total Liabilities

$124.44 Million
USD

Capital Expenditures

$243.00K
USD

Allogene Therapeutics Inc Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for Allogene Therapeutics Inc across 8 annual periods. Check ALLO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Allogene Therapeutics Inc (2017–2024)

Year-by-year free cash flow to debt coverage for Allogene Therapeutics Inc. For the full company profile including market capitalisation, see Allogene Therapeutics Inc market capitalisation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -1.58x $-199.61 Million $-200.30 Million $126.53 Million ▲ +12.8%
2023 -1.81x $-236.22 Million $-237.73 Million $130.60 Million ▼ -29.9%
2022 -1.39x $-215.33 Million $-220.52 Million $154.70 Million ▼ -7.0%
2021 -1.30x $-163.37 Million $-184.81 Million $125.63 Million ▼ -292.3%
2020 -0.33x $-49.13 Million $-115.09 Million $148.21 Million ▲ +66.0%
2019 -0.97x $-86.56 Million $-137.35 Million $88.78 Million ▼ -66.4%
2018 -0.59x $-41.42 Million $-44.65 Million $70.69 Million ▲ +100.0%
2017 -19660.50x $-39.32 Million $-44.65 Million $2.00K
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities